Continue to Site

Drug Discovery and Development

ViiV Healthcare wins FDA nor for long-acting HIV injectable

By |

ViiV Healthcare

ViiV Healthcare has announced the FDA approval of Apretude (cabotegravir), which it bills as the “first and only” long-acting injectable pre-exposure prophylaxis (PrEP) option to reduce the risk of sexually acquired HIV-1.

The drug can be administered as few as six times per year.

The FDA approval covers adults and adults who weigh at least 35 kg and have a negative HIV-1 test before beginning therapy.

ViiV Healthcare is a joint venture between GlaxoSmithKline (LON:GSK), Pfizer (NYSE:PFE) and Shionogi.

“Today’s approval adds an important tool in the effort to end the HIV epidemic by providing the first option to prevent HIV that does not involve taking a daily pill,” said Dr. Debra Birnkrant, director of the Division of Antivirals in the FDA’s Center for Drug Evaluation and Research. “This injection, given every two months, will be critical to addressing the HIV epidemic in the U.S., including helping high-risk individuals and certain groups where adherence to daily medication has been a major challenge or not a realistic option,” Birnkrant said in a statement.

ViiV Healthcare also manufactures cabotegravir tablets known as Vocabria.

It plans to begin shipping Apretude in early 2022.

Filed Under: Infectious Disease

 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development